Oncology Blood Testing Market Size & Share Analysis - Growth Trends And Forecast (2024 - 2031)

• The Oncology Blood Testing Market is expanding rapidly due to the increasing prevalence of cancer worldwide and the rising need for early, non-invasive diagnostic methods.

• Growing adoption of liquid biopsy technologies and circulating tumor DNA (ctDNA) testing is transforming cancer detection and treatment monitoring practices.

• Advancements in molecular diagnostics and next-generation sequencing (NGS) are improving the accuracy, sensitivity, and specificity of oncology blood tests.

• Increasing focus on personalized medicine and targeted cancer therapies is driving demand for biomarker-based blood tests in clinical settings.

• Strategic collaborations between diagnostic companies, pharmaceutical firms, and research institutions are accelerating innovation and commercialization of novel cancer detection tools.

• Rising awareness about the benefits of minimally invasive screening and growing investments in cancer diagnostics infrastructure are further boosting market growth.

• The North American region dominates due to strong R&D capabilities and a well-established healthcare ecosystem, while Asia-Pacific shows rapid expansion fueled by government initiatives and increasing oncology screening programs.

• In September 2025, Exact Sciences launched Cancerguard, a multi-cancer early detection blood test designed to expand access to oncology diagnostics. The test evaluates multiple biomarker classes and operates as a laboratory-developed test, supported by a collection agreement with a major diagnostics network to reach thousands of patient sites.

• In February 2024, Freenome secured substantial investment funding to advance its blood-based cancer detection platform. The financing aims to accelerate pivotal studies, enhance single-cancer and multi-cancer test development, and prepare for large-scale commercialization across healthcare markets.

In this report, the Oncology Blood Testing Market has been segmented by Test Type, Application, End User and Geography.

Oncology Blood Testing Market, Segmentation by Test Type

The Test Type landscape spans screening, diagnosis, therapy selection, and longitudinal disease monitoring, each with distinct performance and workflow needs. Vendors compete on analytical sensitivity/specificity, sample-to-answer time, and bioinformatics that transforms raw signal into actionable insights for clinicians. Commercial strategies emphasize clinical validation, payer-aligned utility, and partnerships that extend test reach across oncology networks and integrated delivery systems while addressing cost-effectiveness and scalability.

Liquid Biopsy Assays

Liquid biopsy assays analyze circulating tumor DNA (ctDNA), cell-free DNA, and other analytes to inform minimal residual disease, early relapse detection, and targeted therapy selection. Growth is propelled by expanding tumor-agnostic biomarkers, improved panels, and real-world evidence that supports use alongside tissue testing. Companies invest in NGS workflows, automated sample prep, and oncology-center partnerships to accelerate adoption across academic and community settings and enable routine treatment monitoring.

CBC (Complete Blood Count) Test

The CBC provides baseline and ongoing evaluation for oncology patients, informing myelosuppression risk, infection monitoring, and therapy modifications. Its ubiquity, low cost, and integration into chemotherapy protocols secure consistent utilization across care sites. Suppliers focus on analyzer reliability, turnaround time, and connectivity with hospital information systems to support throughput and high-quality clinical decision-making.

Blood Protein Test

Blood protein testing tracks proteomic biomarkers related to tumor burden, inflammation, and treatment response. Adoption depends on clinical guidelines, assay standardization, and the ability to complement genetic tests with phenotypic readouts. Vendors prioritize multiplex formats, quality controls, and collaborations that tie biomarker dynamics to outcomes, supporting broader use across oncology sub-specialties and value-based care models.

Tumor Marker Test

Tumor markers such as CEA, CA 15-3, CA 19-9, and others support prognosis and surveillance, particularly in post-treatment follow-up. Market activity centers on better specificity, reflex algorithms, and integration with imaging and molecular testing to improve clinical utility. Differentiation comes from lab automation, reagent stability, and robust reference ranges that enhance interpretability across diverse patient populations and care settings.

CTC (Circulating Tumor Cells)-Based Test

CTC-based tests offer a cellular window into tumor biology for metastatic risk stratification and therapy assessment. While technically demanding, progress in capture/enrichment and single-cell analysis expands relevance in precision oncology. Developers emphasize standardized protocols, clinical utility studies, and partnerships with research consortia to translate insights into routine workflows and strengthen reimbursement readiness.

NIPT (Non-Invasive Prenatal Testing) Test

Although designed for prenatal screening,